Jazz Pharmaceuticals plc Dossier
Qualitative Analysis
Business overview
Jazz Pharmaceuticals plc is a global biopharmaceutical company dedicated to developing and commercializing life-changing medicines for people with serious diseases, with a primary focus on neuroscience (including sleep medicine and epilepsy) and oncology. The company's commercial portfolio is anchored by key high-performing therapies, including Xywav for narcolepsy and idiopathic hypersomnia, Epidiolex/Epidyolex for rare epilepsies, and an expanding oncology franchise featuring Zepzelca, Rylaze/Enrylaze, and the newly launched Modeyso. Jazz is actively executing a strategic pivot toward precision oncology to diversify its revenue streams and mitigate generic competition risks associated with its legacy high-sodium sleep drug, Xyrem.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Expanding and scaling the oncology franchise to diversify revenue away from legacy sleep medicines. Key drivers include the commercial ramp of Modeyso (dordaviprone) in H3 K27M-mutant diffuse midline glioma and preparing for the commercial launch of zanidatamab (Ziihera) in first-line GEA.
Expected impact: Aims to drive double-digit growth in the non-sleep segments, offsetting sleep franchise erosion and establishing oncology as a multi-billion dollar pillar.
Transitioning patients from high-sodium Xyrem to the low-sodium alternative Xywav to preserve market share and mitigate the impact of generic high-sodium oxybate competition.
Expected impact: Maintaining Xywav as the leading branded treatment for narcolepsy and idiopathic hypersomnia, sustaining high-margin cash flows to fund pipeline development.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
Acquired dordaviprone (now marketed as Modeyso), a late-stage treatment for H3 K27M-mutant diffuse glioma, adding a near-term commercial opportunity to the oncology pipeline.
Financial impact: Generated $37 million in its first full quarter on the market (4Q25) and $41.4 million in 1Q26, while also providing over $200 million in reduced cash taxes.
Strategic Partnerships
To discover and develop drug candidates targeting the KRAS inhibitor program, expanding Jazz's oncology pipeline with early-stage targeted therapies.
Terms: Redx to receive $10 million upfront, with potential for up to $870 million in development, regulatory, and commercial milestone payments, plus royalties.